Mr. Mark Upsdell reports

RAPID DOSE ANNOUNCES CANCELLATION OF STOCK OPTIONS AND INTENTION TO REGRANT

Effective Feb. 28, 2024, Rapid Dose Therapeutics Corp. cancelled an aggregate of 5.35 million stock options to purchase common shares of the company, which were previously granted to employees, advisers and consultants of the company (each an optionee) under the company's stock option plan. The company reviewed its outstanding options and determined that certain options granted to such optionees under the plan, at exercise prices ranging from 55 cents to 82 cents per common share, no longer represented an effective incentive to align the interests of such optionees with the corporation. Consequently, the company, in compliance with the policies of the Canadian Securities Exchange (CSE), intends to grant an equal number of options under the plan to such optionees on the day after 30 days will have elapsed from the effective date, at an exercise price equal to the greater of the closing market price of the common shares on the CSE on: (a) the trading day prior to the date of grant of the new stock options; and (b) the date of grant of the new stock options. Such new stock options are being granted to provide a more effective incentive to align the interests of such optionees with the corporation going forward.

About Rapid Dose Therapeutics Corp.

Rapid Dose Therapeutics is a Canadian biotechnology company revolutionizing drug delivery through innovation. The company's flagship product, QuickStrip, is a thin, orally dissolvable film that can be infused with an infinite list of active ingredients, including nutraceuticals, pharmaceuticals and vaccines, that are delivered quickly into the bloodstream, resulting in rapid onset of the active ingredient.

We seek Safe Harbor.